These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 23110550)

  • 1. Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines.
    Martowicz A; Spizzo G; Gastl G; Untergasser G
    BMC Cancer; 2012 Oct; 12():501. PubMed ID: 23110550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth.
    Martowicz A; Rainer J; Lelong J; Spizzo G; Gastl G; Untergasser G
    Mol Cancer; 2013 Jun; 12():56. PubMed ID: 23758908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy.
    Osta WA; Chen Y; Mikhitarian K; Mitas M; Salem M; Hannun YA; Cole DJ; Gillanders WE
    Cancer Res; 2004 Aug; 64(16):5818-24. PubMed ID: 15313925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion.
    Sankpal NV; Mayfield JD; Willman MW; Fleming TP; Gillanders WE
    Breast Cancer Res; 2011; 13(6):R124. PubMed ID: 22132731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
    Hugo HJ; Gunasinghe NPAD; Hollier BG; Tanaka T; Blick T; Toh A; Hill P; Gilles C; Waltham M; Thompson EW
    Breast Cancer Res; 2017 Jul; 19(1):86. PubMed ID: 28750639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.
    Horio M; Sato M; Takeyama Y; Elshazley M; Yamashita R; Hase T; Yoshida K; Usami N; Yokoi K; Sekido Y; Kondo M; Toyokuni S; Gazdar AF; Minna JD; Hasegawa Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3(Suppl 3):S634-45. PubMed ID: 22086445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of EpCAM overexpression on human breast cancer cell lines.
    Gostner JM; Fong D; Wrulich OA; Lehne F; Zitt M; Hermann M; Krobitsch S; Martowicz A; Gastl G; Spizzo G
    BMC Cancer; 2011 Jan; 11():45. PubMed ID: 21281469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis.
    Gao J; Liu X; Yang F; Liu T; Yan Q; Yang X
    Oncotarget; 2015 Sep; 6(29):27187-98. PubMed ID: 26356670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy.
    Yanamoto S; Kawasaki G; Yoshitomi I; Iwamoto T; Hirata K; Mizuno A
    Oral Oncol; 2007 Oct; 43(9):869-77. PubMed ID: 17207659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MTA1-upregulated EpCAM is associated with metastatic behaviors and poor prognosis in lung cancer.
    Zhou N; Wang H; Liu H; Xue H; Lin F; Meng X; Liang A; Zhao Z; Liu Y; Qian H
    J Exp Clin Cancer Res; 2015 Dec; 34():157. PubMed ID: 26698569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma.
    Matsuda T; Takeuchi H; Matsuda S; Hiraiwa K; Miyasho T; Okamoto M; Kawasako K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S356-64. PubMed ID: 24566863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Context-dependent adaption of EpCAM expression in early systemic esophageal cancer.
    Driemel C; Kremling H; Schumacher S; Will D; Wolters J; Lindenlauf N; Mack B; Baldus SA; Hoya V; Pietsch JM; Panagiotidou P; Raba K; Vay C; Vallböhmer D; Harréus U; Knoefel WT; Stoecklein NH; Gires O
    Oncogene; 2014 Oct; 33(41):4904-15. PubMed ID: 24141784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by AP1-dependent EpCAM expression in MCF-7 cells.
    Gao J; Yan Q; Wang J; Liu S; Yang X
    J Cell Physiol; 2015 Apr; 230(4):775-82. PubMed ID: 25205054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EpCAM modulates NF-κB signaling and interleukin-8 expression in breast cancer.
    Sankpal NV; Fleming TP; Gillanders WE
    Mol Cancer Res; 2013 Apr; 11(4):418-26. PubMed ID: 23378578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1.
    Bao B; Azmi AS; Aboukameel A; Ahmad A; Bolling-Fischer A; Sethi S; Ali S; Li Y; Kong D; Banerjee S; Back J; Sarkar FH
    J Biol Chem; 2014 May; 289(21):14520-33. PubMed ID: 24719318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer.
    Subramanian N; Kanwar JR; Kanwar RK; Sreemanthula J; Biswas J; Khetan V; Krishnakumar S
    PLoS One; 2015; 10(7):e0132407. PubMed ID: 26176230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
    Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
    Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
    Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.